This Month:
- General Overview
- First Look at Nolan Williams et al.’s Ibogaine IP: Is Co-Administration of Magnesium and Ibogaine Common Practice?
- Clexio Biosciences Protects CLE-100 Development Programs
- Broad Strokes Attempt from Axsome Fails to Overcome Prior Art
- NYU Abandons “Hot Psilocybin Patent Garbage”
***
General Overview
We added 22 PCTs and 23 patent applications focused on psychedelics to our tracker in the month of February 2024. New entries came from the likes of Axsome Therapeutics, Empyrean Neuroscience, Tactogen, Clexio Biosciences, Gilgamesh Pharmaceuticals, and more.
(Subscribe or sign-in, below, to explore the interactive tables.)
***
First Look at Nolan Williams et al.’s Ibogaine IP: Is Co-Administration of Magnesium and Ibogaine Common Practice?
Last June in Denver at Psychedelic Science 2023, Stanford researcher Nolan Williams1 shared preliminary findings from an observational study that saw ibogaine and magnesium administered to veterans with traumatic brain injuries.
The researcher’s preliminary presentation was very well received and ultimately followed up by a heavily anticipated January 2024 publication that drew a flurry of media attention (see Eagerly Anticipated Ibogaine Study Publishes). In the Nature Medicine article, the authors noted the challenges researchers (past and present) face in their endeavour to study and develop ibogaine into an FDA-approved therapy, owing largely to the drug’s cardiotoxic effects.
Subscribe or sign in to continue reading…
The Psychedelic Patent Analysis: A Pα+ Subscriber Benefit
Each month, we provide an interactive database of psychedelic patents that were granted, allowed, abandoned, rejected or that had responses filed.
We then provide detail and analysis on a handful of specific cases, or one deep dive.
Our monthly Psychedelic Patent Analysis is exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.
Companies, organisations and candidates mentioned in this analysis: DemeRx, Axsome Therapeutics, Empyrean Neuroscience, Tactogen, Clexio Biosciences, CLE-100, Gilgamesh Pharmaceuticals, MindMed, Awakn Life Sciences, and others.
